Microbiology and Immunology

You are here

Home > Publications > Publications

Publications

Found 13 results
Author Title Type [ Year(Asc)]
Filters: Author is Barry, Clifton E  [Clear All Filters]
2025
Green SR, Harrison JR, Thompson S, Murugesan D, M Libardo DJ, Engelhart CA, Meshanni J, Fletcher D, Scullion P, Edwards D et al..  2025.  Identification of a Series Containing a Pentafluorophenyl Moiety That Targets Pks13 to Inhibit Growth of Mycobacterium tuberculosis.. ACS Infect Dis. 11(3):715-726.
2022
Gold B, Zhang J, Quezada LLopez, Roberts J, Ling Y, Wood M, Shinwari W, Goullieux L, Roubert C, Fraisse L et al..  2022.  Identification of β-Lactams Active against Mycobacterium tuberculosis by a Consortium of Pharmaceutical Companies and Academic Institutions.. ACS Infect Dis. 8(3):557-573.
2021
de Melo CSoares, Singh V, Myrick A, Simelane SB, Taylor D, Brunschwig C, Lawrence N, Schnappinger D, Engelhart CA, Kumar A et al..  2021.  Antitubercular 2-Pyrazolylpyrimidinones: Structure-Activity Relationship and Mode-of-Action Studies.. J Med Chem. 64(1):719-740.
Aldridge BB, Barros-Aguirre D, Barry CE, Bates RH, Berthel SJ, Boshoff HI, Chibale K, Chu X-J, Cooper CB, Dartois V et al..  2021.  The Tuberculosis Drug Accelerator at year 10: what have we learned? Nat Med. 27(8):1333-1337.
2019
Beites T, O'Brien K, Tiwari D, Engelhart CA, Walters S, Andrews J, Yang H-J, Sutphen ML, Weiner DM, Dayao EK et al..  2019.  Plasticity of the Mycobacterium tuberculosis respiratory chain and its impact on tuberculosis drug development.. Nat Commun. 10(1):4970.
2018
Oh S, Park Y, Engelhart CA, Wallach JB, Schnappinger D, Arora K, Manikkam M, Gac B, Wang H, Murgolo N et al..  2018.  Discovery and Structure-Activity-Relationship Study of N-Alkyl-5-hydroxypyrimidinone Carboxamides as Novel Antitubercular Agents Targeting Decaprenylphosphoryl-β-d-ribose 2'-Oxidase.. J Med Chem. 61(22):9952-9965.
2015
Nathan C, Barry CE.  2015.  TB drug development: immunology at the table.. Immunol Rev. 264(1):308-18.
2013
Kim J-H, O'Brien KM, Sharma R, Boshoff HIM, Rehren G, Chakraborty S, Wallach JB, Monteleone M, Wilson DJ, Aldrich CC et al..  2013.  A genetic strategy to identify targets for the development of drugs that prevent bacterial persistence.. Proc Natl Acad Sci U S A. 110(47):19095-100.
2011
Duckworth BP, Geders TW, Tiwari D, Boshoff HI, Sibbald PA, Barry CE, Schnappinger D, Finzel BC, Aldrich CC.  2011.  Bisubstrate adenylation inhibitors of biotin protein ligase from Mycobacterium tuberculosis.. Chem Biol. 18(11):1432-41.
Park SWoong, Klotzsche M, Wilson DJ, Boshoff HI, Eoh H, Manjunatha U, Blumenthal A, Rhee K, Barry CE, Aldrich CC et al..  2011.  Evaluating the sensitivity of Mycobacterium tuberculosis to biotin deprivation using regulated gene expression.. PLoS Pathog. 7(9):e1002264.
Shi C, Geders TW, Park SWoong, Wilson DJ, Boshoff HI, Abayomi O, Barry CE, Schnappinger D, Finzel BC, Aldrich CC.  2011.  Mechanism-based inactivation by aromatization of the transaminase BioA involved in biotin biosynthesis in Mycobaterium tuberculosis.. J Am Chem Soc. 133(45):18194-201.
2009
Barry CE, Boshoff HI, Dartois V, Dick T, Ehrt S, Flynn JA, Schnappinger D, Wilkinson RJ, Young D.  2009.  The spectrum of latent tuberculosis: rethinking the biology and intervention strategies.. Nat Rev Microbiol. 7(12):845-55.
2008
Boshoff HIM, Xu X, Tahlan K, Dowd CS, Pethe K, Camacho LR, Park T-H, Yun C-S, Schnappinger D, Ehrt S et al..  2008.  Biosynthesis and recycling of nicotinamide cofactors in mycobacterium tuberculosis. An essential role for NAD in nonreplicating bacilli.. J Biol Chem. 283(28):19329-41.